Navigation Links
Par Pharmaceutical Companies Reports Third Quarter 2011 Results
Date:11/2/2011

Access to the live webcast can be made via the Company's website at www.parpharm.com.Dial-in InformationDomestic:

800-901-5241International:

617-786-2963Passcode:

52087832A replay of the conference call will be available for two weeks approximately one hour after the call.  Replay InformationDomestic:

888-286-8010International:

617-801-6888Passcode:

42213272Non-GAAP MeasuresPar Pharmaceutical Companies, Inc. ("the Company") believes it prepared its unaudited condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP) and pursuant to accounting requirements of the Securities and Exchange Commission.  In an effort to provide investors with additional information regarding the Company's results and to provide a meaningful period-over-period comparison of the Company's financial performance, the Company sometimes uses non-GAAP financial measures as defined by the Securities and Exchange Commission.  The differences between the U.S. GAAP and non-GAAP financial measures are reconciled in an attached schedule.  In presenting comparable results, the Company discloses non-GAAP financial measures when it believes such measures will be useful to investors in evaluating the Company's underlying business performance.  Management uses the non-GAAP financial measures to evaluate the Company's financial performance against internal budgets and targets.  In addition, management internally reviews the Company's results excluding the impact of certain items, as it believes that these non-GAAP financial measures are useful for evaluating the Company's core operating results and facilitating comparison across reporting periods.  Importantly, the Company believes non-GAAP financial measures should be considered in addition to, and not in lieu of, U.S. GAAP financial measures.  The C
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014  Come fall, many children, teenagers, and ... they want to be for Halloween. And, a number ... decorative contact lenses bought without a prescription. ... people purchase and wear contact lenses without a prescription. ... ® consumer survey, 17 percent of Americans have ...
(Date:9/30/2014)... Sept. 30, 2014 Chindex ... CHDX ) today announced the completion of its acquisition ... per share in cash.  Healthy Harmony is an affiliate ... and Ms. Roberta Lipson , the CEO of ... was adopted by Chindex,s stockholders at a special meeting ...
(Date:9/30/2014)... CARLOS, Calif. , Sept. 30, 2014 /PRNewswire/ ... an additional $10 million investment from current investors ... The additional financing was completed following achievement of ... lead antibody program, and represents an extension of ... closed in December 2012. With this additional financing, ...
Breaking Medicine Technology:The Spooky Truth: What You Need To Know About Contact Lens Hygiene 2The Spooky Truth: What You Need To Know About Contact Lens Hygiene 3Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 2Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 3Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 4Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 5Allakos Inc. Raises Additional $10 Million to Expand its Portfolio and Fund Development of an Additional Antibody for Allergic and Inflammatory Diseases 2Allakos Inc. Raises Additional $10 Million to Expand its Portfolio and Fund Development of an Additional Antibody for Allergic and Inflammatory Diseases 3Allakos Inc. Raises Additional $10 Million to Expand its Portfolio and Fund Development of an Additional Antibody for Allergic and Inflammatory Diseases 4
... BALTIMORE, May 5, 2011 New data presented ... Interventions (SCAI) Scientific Sessions are the first to ... within implantable cardioverter defibrillators (ICDs) to detect restricted ... disease patients outside the hospital setting. Preliminary results ...
... 5, 2011 Echo Therapeutics, Inc. (OTCBB: ECTE), a ... wireless, transdermal continuous glucose monitoring (tCGM) system and the ... the relocation of its corporate headquarters from Franklin, MA ... located in the heart of Philadelphia,s Center City Business ...
Cached Medicine Technology:New Data Provide First Look at Ability to Detect Life-Threatening Heart Problems in Some High-Risk Patients 2New Data Provide First Look at Ability to Detect Life-Threatening Heart Problems in Some High-Risk Patients 3Echo Therapeutics Expands Into New Headquarters in Philadelphia 2
(Date:9/30/2014)... 2014 Lea Blackwell, M.D., a Breast ... patients a new, more practical and comfortable option for ... mastectomies, biopsies and lumpectomy surgeries use special bras after ... seeing her patients describe the bra as scratchy, uncomfortable ... new bra in her spare time. , Ilona ...
(Date:9/30/2014)... California (PRWEB) September 30, 2014 ... to reach USD 8,020.1 million by 2020, according ... Inc. Growing demand for personalized medicine and theranostics, ... technologies are expected to be key factors driving ... the growing global base of geriatric population and ...
(Date:9/30/2014)... During this online virtual event, hear ... including achieving hormonal balance, relieving menopause symptoms, breast ... , The details of the virtual ... 2014, Location: Online Event, Registration: Complimentary , Visit ... Monday, October 6th, Steven F. Hotze, M.D., David ...
(Date:9/30/2014)... Oxnard, CA (PRWEB) September 30, 2014 ... the Anacapa Dental Art Institute in Oxnard and Thousand ... Bangalore today and tomorrow to provide training on full ... previous dental work, placing implants, providing cosmetic dentistry, correcting ... Dr. Jivraj said. , Dr. Jivraj, who has traveled ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 ... ADVISORY** , From:        Hope For ... 910.554.1505, abarnwell(at)hopeforthewarriors(dot)org , ... Celebration , Date:        Thursday, October ... Army and Navy Club, ...
Breaking Medicine News(10 mins):Health News:Surgeon Creates New Bra for Breast Cancer Patients, Post-Surgery 2Health News:Surgeon Creates New Bra for Breast Cancer Patients, Post-Surgery 3Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 2Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 3Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 4Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 5Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 6Health News:Hotze Health & Wellness Center Announces First Natural Health Summit 2Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 2Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 3Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 4Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 5Health News:Hope For The Warriors' Got Heart, Give Hope Celebration Media Advisory 2
... American Oriental,Bioengineering, Inc. (NYSE: AOB ), ... nutraceutical products in China, today,announced that the Company ... Company will present at the CIBC World Markets ... at the Waldorf-Astoria,Hotel in New York City. Management ...
... Now Able to Submit Aetna Claims at No Cost ... Inc., a leading,healthcare technology company focused on providing innovative ... today,announced it has expanded its relationship with Aetna to ... 1, 2007. Aetna is a leading,diversified health care benefits ...
... Health Care Costs, DALLAS, Oct. 26 ... M.D., M.P.H., Cooper Aerobics Enterprises,Inc., announced today its ... Enterprises purchased Health At Work, a licensed,health, life ... Cooper Benefits,LLC. Cooper Benefits merges traditional employee ...
... WEST BERLIN, N.J., Oct. 26 EP MedSystems,(Nasdaq: EPMD ) announces the following ... 11/01/2007 @ 4:30 pm EST, Where: ... Simply log on to the web at the ... person of EP MedSystems, ...
... Jack Group, Inc.,(MattsonJack) announces the release of its ... help clients make strategic,decisions based on an in-depth ... conditions. Comorbidity Database(TM) consists of,two modules: Comorbidity Database(TM) ... and Comorbidity Database(TM) -- Med 2.0, which features ...
... Institutet have shown that hysterectomy a common operation ... the risk of urinary incontinence. Their results, which ... Lancet. , Hysterectomy is the most common gynaecological ... as a cure for benign medical problems in order ...
Cached Medicine News:Health News:American Oriental Bioengineering Announces Participation in November Healthcare Conferences 2Health News:MD On-Line Expands Relationship with Aetna for Direct Claim Submission 2Health News:An Industry First: New Cooper Health Company Makes Group Employee Benefits Consulting and Wellness Program Design a Package Deal 2Health News:An Industry First: New Cooper Health Company Makes Group Employee Benefits Consulting and Wellness Program Design a Package Deal 3Health News:An Industry First: New Cooper Health Company Makes Group Employee Benefits Consulting and Wellness Program Design a Package Deal 4Health News:Webcast Alert: EP MedSystems Announces EP MedSystems Third Quarter 2007 Earnings Conference Call Webcast 2Health News:The Mattson Jack Group, Inc. Announces the Release of the New Comorbidity Database(TM) 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: